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Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT
(SLC22) and PEPT (SLC15) transporters in the intestine, liver
and kidney
Abstract
The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become
increasingly evident with the discovery of genetic variants that affect expression and/or function of a
given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as intestinal
epithelial cells, hepatocytes, renal tubular cells and at the blood-brain barrier. Several recent studies
have associated alterations in substrate uptake with the presence of SNPs. Here, we summarize the
current knowledge on the functional and phenotypic consequences of genetic variation in intestinally,
hepatically and renally expressed members of the organic anion-transporting polypeptide family
(OATPs; SLC21/SLCO family), the organic anion and organic cation transporters (OATs/OCTs; SLC22
family) and the peptide transporter-1 (PEPT1; SLC15 family).
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Summary 
 
The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become 
increasingly evident with the discovery of genetic variants that affect expression and/or function of a 
given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as intestinal 
epithelial cells, hepatocytes, renal tubular cells and at the blood-brain barrier. Several recent studies 
have associated alterations in substrate uptake with the presence of single nucleotide polymorphisms 
(SNPs). Here we summarize the current knowledge on the functional and phenotypic consequences of 
genetic variation in intestinally, hepatically and renally expressed members of the organic anion 
transporting polypeptide family (OATPs; SLC21/SLCO family), the organic anion and organic cation 
transporters (OATs/OCTs; SLC22 family) and the peptide transporter-1 (PEPT-1; SLC15A family).  
 
 
 
 
 
 
 
 
Keywords: drug transporters, pharmacokinetics, single nucleotide polymorphisms, PEPT-1, organic 
anion transporting polypeptides, organic anion transporter proteins, organic cation transporters, 
farnesoid X receptor, estrone-3-sulfate, statins.  
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Individual variation in drug response makes effective drug prescribing a clinical challenge, particularly 
with drugs that have a narrow therapeutic window. While current dosage regimes may prove 
therapeutically effective in most patients, others experience no beneficial effect or worse still suffer 
drug toxicity. Drug response is determined by factors influencing pharmacokinetics and 
pharmacodynamics. Pharmacodynamics refers to the association between drug concentration and the 
biological effects of the drug, while pharmacokinetics describes the relationship between the drug 
concentration in the body over time. Pharmacokinetics encompasses drug absorption, drug distribution, 
drug metabolism and drug excretion (ADME). The role of transporters in determining pharmacokinetics 
has become all the more evident with the discovery of genetic variants that influence drug transporter 
function or expression levels.  
 
 
The passage of drugs through the body 
 
While every tissue has some ability to transport and metabolize drugs, it is the intestine, liver, and 
kidneys that are the principal organs of drug absorption, metabolism and excretion. Transport and 
metabolism of drugs can be divided into four phases, 0 – III. Phase 0 refers to the drug uptake processes, 
phase I describes oxidative, reductive and hydrolytic drug metabolism, predominantly mediated by 
cytochrome P450 (CYP) enzymes, although other enzymes such as flavin-containing monooxygenases 
(FMOs) are also involved. In phase II, drugs and phase I metabolites are further detoxified by enzymes 
via conjugation reactions and phase III efflux carriers are responsible for the excretion of drugs. 
 
Oral administration is the most common and convenient method by which drugs are administered. The 
principle site for the absorption of orally administered drugs is the gastrointestinal tract. Intestinal 
absorption of most drugs is dependent on uptake transporters expressed at the brush border membrane 
of enterocytes (Figure 1) (1). These include the peptide transporter-1 (PEPT-1), the organic anion 
transporting polypeptide 2B1 (OATP2B1) and the organic anion transporting polypeptide 1A2 
 4
(OATP1A2), although the presence of OATP1A2 in the enterocyte, is controversial (2, 3) (Figure 1, 
Table 1). Efflux transporters, also present at the intestinal brush border membrane (Figure 1), reduce the 
oral bioavailability of drugs. Efflux transporters typically belong to the ATP-binding cassette (ABC) 
transporter superfamily (4). 
 
Following uptake by enterocytes, drugs are translocated across the basolateral enterocyte membrane into 
the portal blood circulation, by the action of drug efflux pumps. An important pharmacokinetic 
determinant is the degree of hepatic extraction, mediated by the organic anion transporting polypeptides 
(OATPs), organic anion transporters (OATs) and organic cation transporters (OCTs), expressed at the 
sinusoidal (basolateral) membrane of hepatocytes (Figure 1). In the liver, drugs may undergo 
metabolism by phase I and/or phase II enzyme reactions (5). Sufficiently polarized metabolites are then 
excreted by efflux carriers either expressed at the apical canalicular membrane, such as the ABC family 
transporters MDR1, MRP2 and ABCG2, or at the basolateral membrane, such as MRP3, MRP4 and 
MRP5 (4). 
 
In addition to hepatic metabolism and excretion, renal excretion is the second major route of elimination 
where drug transporters play a pivotal role. Renal tubular epithelial cells express drug transporters at 
both the basolateral and the apical plasma membrane domains, allowing for the tubular excretion of 
drugs and drug metabolites. In addition to the enterohepatic and renal membrane barriers, transport 
proteins also exist at the blood-brain, blood-testis and blood-placenta barriers where their predominant 
function is to limit the penetration of toxins, thus providing a protective mechanism (6-9).  
 
Factors that influence pharmacokinetics such as age, co-medication and gender have long been 
considered in the administration of drugs. It is becoming increasingly evident that a patient’s genotype 
may also markedly influence drug response, introducing the concept of individualized drug therapy. 
Here we will review the current knowledge on genetic polymorphisms in selected drug transporters 
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expressed in human intestine, liver and kidney, focusing on members of the SLC21/SLCO, SLC22 and 
SLC15 drug transporter families.  
 
Drug Transport in the Intestine 
 
While some drugs can pass through the intestinal wall via transcellular and paracellular diffusion, most 
drugs require carrier-mediated transport mechanisms (Figure 1). Indeed, a wide variety of transporters 
expressed along the intestine are involved in the membrane transport not only of nutrients but also of 
drugs.  
 
The Peptide Transporter PEPT-1 
The secondary active uptake transporter, PEPT-1, is predominantly localized at the apical membrane of 
absorptive enterocytes of the duodenum, jejunum and ileum (3, 10, 11). PEPT-1 is responsible for the 
active absorptive influx of dietary di- and tripeptides in addition to hydrophilic drugs such as β–lactam 
antibiotics (12, 13) and angiotensin-converting enzyme (ACE) inhibitors (14). Due to the broad 
specificity of PEPT-1, its utilization as a target for oral drug delivery is a promising strategy. Hence, 
knowing the effects of genetic variation on PEPT-1 transporter function may have a marked impact on 
the development of oral drug delivery. 
 
To date 40 coding polymorphisms and over 100 haplotypes have been identified in the SLC15A1 gene, 
encoding PEPT-1 (15, 16). Although the allelic frequencies of many SNPs are low, a degree of ethnic 
bias has been observed for some of them. The SNPs 83T>A (F28Y) and 351C>A (S117R), for instance, 
are present only in African-Americans, while 1848G>A (L616L) is specific to Caucasians (15, 16). 
Using HEK293 cells, HeLa cells and Xenopus laevis oocytes as transport model systems, the two most 
commonly occurring SNPs 351G>A (S117N) and 1256G>C (G419A), have been tested for the transport 
of several substrates including glycyl-sarcosine (Gly-Sar), bestatin, 5-aminolevulinic acid 
hydrochloride, enalapril, cefadroxil, captopril, L-DOPA and cephalexin (15-17) (Figure 2, Table 2). In 
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all instances PEPT-1-S117N (351G>A) and PEPT-1-G419A (1256G>C) were shown to exhibit similar 
uptake of all substrates when compared to the wild type protein (15-17). 
 
Functional characterization of genetic variants of PEPT-1 has been performed by testing for the 
transport of the model substrate Gly-Sar (16). All protein variants, except PEPT-1-P586L (1758C>T), 
were shown to transport Gly-Sar in a pH dependent manner to a similar degree and to be expressed at a 
comparable level to the wild type protein (16). The rare protein variant PEPT-1-P586L (1758C>T), 
showed reduced transport of Gly-Sar, possibly due to the reduced expression of the PEPT-1 protein 
variant, as demonstrated by immunoblotting and immunocytochemistry in vitro (16). The presence of 
the SNP 83T>A (F28Y), expressed exclusively within the African-American population (15), also led to 
a reduction in the transport of Gly-Sar (15). Further analysis revealed that whereas the PEPT-1-F28Y 
(83T>A) protein variant was expressed to a similar level to wild type, its affinity for dipeptides was 
lower (15).  
 
It is apparent that the presence of non-synonymous SNPs bears an impact on the function of a transport 
protein, by altering either protein expression levels or binding site affinity. Nonetheless not all non-
synonymous SNPs affect function: in the case of PEPT-1, this holds true for SNPs commonly found in 
most ethnic populations (16).  
 
Future studies should also address the effects of SNPs on other intestinal membrane carriers, such as the 
organic cation/carnitine transporter 1 and 2 (OCTN1 and OCTN2). OCTN1 is a pH-dependent cation 
transporter (18), while OCTN2 transports carnitine in addition to cations (19). Genetic variants of 
OCTN1 and OCTN2 have been associated with inflammatory bowel disease (IBD) (20-22). Moreover 
the OCTN1 protein variant L503F (1507C>T) has been shown to alter transport of the antiepileptic 
drug, gabapentin (23).  
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Drug Transport in the Liver 
 
Hepatic drug uptake from the sinusoidal blood occurs, across the basolateral membrane of hepatocytes, 
via a series of influx carriers (Figure 1). These include the organic anion transporters (OAT), organic 
cation transporters (OCT) and the organic anion transporting polypeptide family (OATP). Among the 
OAT family, OAT2  (gene symbol SLC22A7) is predominantly expressed in the liver (24) and transports 
several antiviral drugs as well as prostaglandins (25, 26). Several race-specific SNPs been reported for 
OAT2, including 329C>T (T110I) in Sub-Saharan Africans, 571G>A (V192I) in Indo-Pakistanis and 
1520 G>A (G507D) in Japanese subjects (27). Little is known, however, about the effect these SNPs 
may have on the substrate specificity or on the transport function of OAT2. Among the OCT family 
OCT1 is highly expressed in the liver although it is also found in other tissues such as the heart and 
lung. OATPs transport both organic anions and organic cations in addition to neutral compounds, 
zwitterionic compounds and peptidomimetic agents (28-30). At least eight OATP members are present 
in humans (31), amongst which OATP1B1 and OATP1B3 are exclusive to the liver. OATP2B1 is also 
expressed in the liver, although it has a wider tissue distribution in the body.  
 
 
OCT1 
OCT1 (gene symbol SLC22A1) is an electrogenic uniporter that translocates a variety of organic cations, 
in both directions across the plasma membrane, independent of sodium or proton gradients (32, 33). 
Predominantly expressed in the liver (34-36), OCT1 mediates the elimination of many drugs as well as 
endogenous bioactive amines. 
 
Genotyping studies have identified over 200 SNPs in the SLC22A1 gene, some of which are race-
dependent (Table 2). Of the SNPs isolated 41C>T (S14F), 181C>T (R61C), 262T>C (C88R), 480C>G 
(F160L), 659G>T (G220V), 848C>T (P283L), 859C>G (R287G), 1022C>T (P341L), 1203G>A 
(G401S), 1222A>G (M408V), 1260delATG (M420del) and 1393G>A (G465R) have been analyzed for 
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their effects on substrate import by OCT1 (37-42). The OCT1 protein variants R61C (181C>T), C88R 
(262T>C), G220V (659G>T), P341L (1022C>T), G401S (1203G>A) and G465R (1393G>A) have all 
been associated with reduced uptake of the toxin, 1-methyl 1-4-phenylpyridinium (MPP) in vitro (37, 
40, 42). Furthermore the OCT1 protein variants C88R (262T>C) and G401S (1203G>A), exhibited 
small but significant uptake activity for tetraethylammonium bromide (TEA) and serotonin, while very 
little MPP mediated transport was observed (42). The SNP 41C>T (S14F), identified in African-
Americans, is associated with increased uptake of MPP (40). As 41C>T (S14F) and 1203G>A (G401S) 
are both expressed in African-Americans, haplotype analysis would offer a clear insight into the 
differences between 41C>T (S14F) and 1203G>A (G401S) and MPP uptake. 
 
Asian subjects expressing the 848C>T (P283L) and 859C>G (R287G) SNPs also showed significant 
reduction in the transport of MPP and TEA with a reduction in Km and Vmax (37, 43). The SNPs 
848C>T (P283L) and 859C>G (R287G) are located within the highly conserved major facilitator 
superfamily (MFS) motif. It remains to be elucidated whether OCT1 orthologs exhibit altered substrate 
uptake as a result of 848C>T (P283L) and 859C>G (R287G) polymorphisms.  
 
Metformin, used widely in the treatment of type-2 diabetes, has been shown as an OCT1 substrate in 
vitro (44). The protein variants S14F-OCT1 (41C>T), R61C (181C>T), S189L-OCT1 (566C>T), 
G401S-OCT1 (1203G>A), 420del-OCT1 (1260delATG) and G465R (1393G>A) are associated with a 
reduction or loss of metformin uptake, as a result of lowered Vmax values, when compared to the 
reference protein (45). Of interest, although not statistically significant, is the increase in metformin 
influx by the M408V (1222A>G) protein variant present in African-Americans (40, 45). Further clinical 
studies, on healthy volunteers, showed that while plasma glucose levels were similar between 
individuals expressing OCT1-M408V (1222A>G) and the reference protein, metformin treatment 
resulted in significantly elevated plasma glucose concentrations and prolonged plasma insulin levels in 
subjects expressing OCT1-M408V (1222A>G) (45). Patients showing little or no response to metformin 
treatment were associated with a lower frequency of the 1222A>G SNP (46). This observation is of 
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interest in view of the fact that metformin is eliminated by the kidney, whereas the antidiabetic action of 
metformin is dependent upon uptake into hepatocytes. SLC22A1 expressing the 1222A>G (M408V) 
SNP had equal if not slightly elevated levels of OCT1 mRNA (46),  removing the possible explanation 
of reduced metformin uptake to occur as a result of reduced OCT1 mRNA expression.   
 
 
OATP1B1 
OATP1B1 (gene symbol SLCO1B1), previously termed OATP-C, OATP-2 or liver-specific  
transporter-1, translocates a broad range of compounds including bile acids, sulfate and glucuronide 
conjugates and peptides (47-49). To date 44 polymorphisms have been identified in the coding region of 
OATP1B1, 20 of which are non-synonymous (Table 2, Figure 3a). Several investigating groups have 
highlighted the race-dependent nature of these SNPs in a number of ethnic groups, including Asians, 
Europeans and African-Americans (50-52). The OATP1B1*5 allele containing the 521T>C (V174A) 
SNP, for instance, is present in European-Americans (52), whereas OATP1B1*9 (1463G>C, G488A) is 
expressed in African-Americans (52) and OATP1B1*15 (388A>G (N130D) + 521T>C) is only present 
in Japanese and Korean subjects (51, 53).  Intriguingly the 521T>C (V174A) SNP, although expressed 
in Asians and Europeans alike, is only prevalent in Asian subjects when the 388A>G (N130D) variant is 
also expressed, unlike the European population who appear to carry the 521T>C (V174A) SNP alone. 
The ancestral significance between the OATP1B1*5 and OATP1B1*15 alleles remains to be elucidated. 
  
While the relevance of non-synonymous SNPs on OATP1B1 transport activity has been explored using 
a variety of substrates, several studies have yielded conflicting data making it difficult to draw any 
tangible conclusions. Initial studies on OATP1B1*5, using HeLa cells as a transient expression system 
for instance, revealed transport activity for estradiol-17β–D-glucuronide and estrone-3-sulfate to be less 
than 50 % when compared to the reference allele OATP1B1*1a (52). In contrast, Nozawa et al., (51) 
reported no significant difference in estrone-3-sulfate transport between OATP1B1*5 and wild type in 
HEK293 cells. Studies by Iwai et al., (54) also showed similar Km values for the transport of estradiol-
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17β–D-glucuronide in HEK293 cells expressing OATP1B1*1a, OATP1B1*5, OATP1B1*15 or the 
OATP1B1*1b reference allele. OATP1B1*1b was the first OATP1B1 transporter identified (55) and 
differs from OATP1B1*1a by the presence of the 388A>G (N130D) SNP. Discrepancies in the transport 
of estradiol-17β–D-glucuronide and estrone-3-sulfate were thought to be attributable to the different in 
vitro expression systems used. However Kameyama et al., (56) excluded this possibility by showing 
altered transport of estradiol-17β–D-glucuronide and estrone-3-sulfate in both HeLa and HEK293 cells 
expressing OATP1B1*5 or OATP1B1*15 (56). Such transport experiments showed the uptake of 
estradiol-17β–D-glucuronide and estrone-3-sulfate by the OATP1B1*5 protein variant to be less than or 
around 50 % when compared to OATP1B1*1a (56). In vivo investigation of estradiol-17β–D-
glucuronide and estrone-3-sulfate transport may be worthwhile in elucidating the actual effects of the 
polymorphisms in the OATP1B1*5 and OATP1B1*15 alleles on their transport activity. 
 
An association between the 521T>C (V174A) SNP in the Japanese and European populations and statin 
uptake has also been identified. Statins are a group of drugs designed to reduce cholesterol synthesis by 
inhibiting 3-Hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase and are used widely for the 
treatment of hypercholesterolemia.  Nishizato et al., (57) reported a gene dosing effect of pravastatin 
plasma concentration such that higher levels were prevalent in homozygotes carrying the OATP1B1 
genotype 521C>C, when compared with heterozygotes carrying the 521T>C genotype. It is therefore 
reasonable to assume that patients carrying the homozygous 521CC genotype would be more 
susceptible to the side effects associated with statins, including cytotoxicity and myopathy. Indeed 
several in vivo studies have shown 521CC homozygotes to exhibit more profound myopathy (57-60), 
confirming previous findings (57, 59). Significant associations were further shown between the 
OATP1B1*5 allele and pravastatin (50, 59, 61). Carriers of the 521T>C (V174A) SNP exhibited higher 
pravastatin plasma levels, when compared to carriers of the reference allele OATP1B1*1a or 
OATP1B1*1b (50, 59, 61). Unlike OATP1B1*15, the effects of OATP1B1*5 on pravastatin plasma 
concentration were not dependent upon zygosity (50).   
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Uptake of other statins, including rosuvastatin and pitavastatin, is also altered in patients carrying the 
OATP1B1 SNP 521T>C (V174A) (62-64). Chung et al., (63) showed increased pitavastatin plasma 
concentrations in Korean subjects expressing the OATP1B1*15 allele. Lee et al., (64) showed an 
increased exposure to rosuvastatin in three Asian groups when compared with Caucasians whereas Ho 
et al., (62) showed a decrease in rosuvastatin uptake in HeLa cells transfected with the OATP1B1*15 
and OATP1B1*5 variants. Differences between data obtained in vitro and in vivo, highlights the need 
for larger in vivo drug studies.  
 
The overall importance of the 521T>C (V174A) SNP for OATP1B1 function is becoming increasingly 
apparent in the altered pharmacokinetics of several drugs (50, 65-67). It would be of interest to know 
whether the OATP1B1-V174A (521T>C) protein is altered in its structure or localization. Cells 
transfected with OATP1B1*18 (50), for example, showed impaired maturation whereby most of the 
protein remained intracellular thereby reducing total protein expression (68). The amino acid 
substitution L193R (578T>G), present in the OATP1B1*18 allele and located to the same 
transmembrane domain as V174A (521T>C) (50, 68) (Figure 3a),  is responsible for the altered 
localization of the OATP1B1*18 protein variant (68). It would be reasonable to suggest therefore that 
the fourth transmembrane domain (Figure 3a) is important for correct substrate recognition, protein 
maturation and thus the transport activity of OATP1B1.   
 
In addition to SNPs in the protein coding regions of transporter genes, polymorphisms in their promoter 
regions may affect binding of transcription factors to their response elements, thereby altering drug 
transporter expression levels and consequently their functional activity. Several SNPs have been 
identified in the promoter region of the SLCO1B1 gene in Japanese subjects (69) where one variant has 
been shown to have an effect on OATP1B1 transporter function. Niemi et al., reported the association 
of SNP -11187G>T, located in the promoter region of the SLCO1B1 gene, with increased pravastatin 
transport (50) and altered blood glucose concentration of the antidiabetic agent repaglinide (66). 
Interindividual variation of OATP1B1 mRNA expression, nevertheless, was associated with the 
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expression levels of the liver-enriched transcription factor Hepatic nuclear factor 1- α (HNF-1α) rather 
than the -11187G>T SNP (70). Indeed, a functional response element for HNF-1 α has been identified 
within the promoter region of the SLCO1B1 gene (71). The exact transcriptional mechanism that 
orchestrates HNF1α mediated transcription of the OATP1B1 variants, however, has yet to be 
determined. 
 
 
 
OATP1B3 
Since its identification in 2000 (72), little is known about the effect of polymorphisms on the transport 
activity of OATP1B3 (gene symbol: SLCO1B3), previously known as OATP-8 or liver-specific  
transporter-2. The liver-specific transporter has 80 % homology to OATP1B1 and shares an overlapping 
range of substrates albeit with differences in affinity (47, 72, 73).  
 
Initial investigation of interindividual variation in SLCO1B3 identified several SNPs in the Japanese 
population, of which 334T>C (S112A) was non-synonymous (69) (Figure 3b). Subsequent studies have 
confirmed the presence of 334T>C (S112A) in Japanese subjects (74), in addition to its presence in 
African-American and European-American populations (75). The polymorphism 699G>A (M233I), has 
also been identified in all ethnic groups studied (75). The allelic frequencies of 334T>C (S112A) and 
699G>A (M233I) were comparable between Caucasians and Asians and thus thought to be independent 
of race (74, 75). These findings were later confirmed in a study that screened 475 patients of Caucasian-
European, Caucasian-American, African-American, Mexican, Han Chinese and Ghanian origin (76). 
Analysis of blood samples from European subjects led to the identification of a third rare SNP, 
1564G>T (G522C) (75), which is not present in any of the other ethnic groups studied (76).  
 
Of the three SNPS identified, 1564G>T (G522C) was found to affect the localization of OATP1B3 
whereby a large portion of the variant protein remained intracellular, within the canine kidney derived 
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cell line MDCKII (75). This phenomenon was cell line specific, as stable transfection of 1564G>T 
(G522C) in the human embryonic kidney cell line, HEK293, revealed OATP1B3-G522C (1564G>T) to 
be localized to the plasma membrane. Impaired glycosylation of OATP1B3-G522C (1564G>T) was, 
however, observed in both cell lines when compared with the reference OATP1B3 protein (75). 
 
Studies have revealed that the presence of 1564G>T (G522C) abolishes the carrier-mediated activity of 
the bile acid cholyltaurine and reduces the transport of bromosulphophthalein and estrone-3-sulfate (75). 
Further transport analysis using the substrates paclitaxel and estrone-3-sulfate showed little difference in 
transport activity between OATP1B3-M233I (699G>A), OATP1B3-S112A (334T>C) and the reference 
OATP1B3 protein (75, 76).  
 
It is worth noting that OATP1B3 is the only OATP family member able to transport the cardiac 
glycoside, digoxin and the octapeptide cholecystokinin (CCK-8) into hepatocytes (47, 77). It would be 
of interest, therefore, to study the effects of genetic variants of OATP1B3 on the transport of these 
OATP1B3-specific substrates in vivo.   
 
Genetic variants of the farnesoid X receptor (FXR), a known transcriptional regulator of the SLCO1B3 
gene (78), have also been shown to alter the expression level of OATP1B3 (79). Individuals 
heterozygous for FXR*1B exhibited lower mRNA levels of OATP1B3 when compared to homozygotes 
for the reference protein FXR*1A, in the liver (79). The FXR*1B allele contains the non-synonymous 
SNP -1G>T, immediately 5’ to the translational start site. Although -1G>T lies within the FXR Kozak 
consensus motif, no marked alterations were observed in the translational efficiency or protein 
maturation of the FXR protein variant in HepG2 cells (79). In contrast, however, reduced translation 
efficiency of FXR*1B was observed in HEK293T cells (80), suggesting FXR regulation to be cell line 
specific. 
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OATP2B1 
OATP2B1 (gene symbol SLCO2B1), previously identified as OATP-B, is located to the basolateral 
membrane of hepatocytes and to the apical membrane of intestinal epithelial cells (81) and transports 
bromosulphophthalein, estrone-3-sulfate, dehydroepiandrosterone sulphate and fexofenadine  (31, 82). 
Transport of cholyltaurine and pravastatin has only been observed at acidic pH (82). Although less 
intensively studied, the SLCO2B1 gene does contain two non-synonymous SNPs (83), assigned the 
allelic names OATP-B*2 (1175C>T, T392I) and OATP-B*3 (1457C>T, S486F) (51). Only the OATP-
B*3 allele was identified in Japanese subjects with a high allelic frequency of 30.9% (51). Significant 
decreases in Vmax were observed for the transport of estrone-3-sulfate in HEK293 cells transfected with 
OATP-B*2 or OATP-B*3, suggesting the 1175C>T (T392I) and 1457C>T (S486F) SNPs to cause a 
decrease in transport activity without affecting substrate affinity (51). 
 
 
 
 
Drug Transport in the Kidney 
 
Most drugs, which undergo tubular secretion, are either anionic or cationic. Drug import carriers, 
expressed at the basolateral domain of renal tubular epithelial cells include the organic anion 
transporters (OAT) and organic cation transporters (OCT) (Figure 1).  Multidrug and toxin extrusion 
transporter 1 (MATE1; gene symbol SLC47A1) (84) and multidrug and toxin extrusion transporter 2-K 
(MATE2-K; gene symbol SLC47A2) (85), also known to transport anionic and cationic compounds, are 
localized to the brush border membrane of renal cells thus providing a vectorial transport system across 
the cell (85, 86).  MATE1 and MATE2-K function as H+/organic cation antiporters, in the transport of  
TEA, MPP, cimetidine, cephalexin and oxaliplatin  (86-88). There is currently no published data 
showing the prevalence of MATE1 or MATE2-K SNPs in distinct ethnic groups or their impact upon 
transporter function.  
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OATs and OCTs actively translocate substrates across the cell against an electrochemical gradient, in 
the case of OATs, dicarboxylate, such as α-ketoglutarate are exchanged (35, 89). The SLC22 family 
members OAT1, OAT3 and OCT2 are highly expressed in the kidney.  
 
 
OAT1           
OAT1 (gene symbol SLC22A6), originally named the novel kidney transporter (NKT) (24, 90), exhibits 
several race-specific SNPs (27, 91, 92). The non-synonymous SNP 20T>C (L7P) is exclusively 
expressed in Southeast Africans (27), while 149G>A (R50H) is present in Sub-Saharan Africans, 
African-Americans and Mexican-Americans (27, 92) and 311C>T (P104L), 767C>T (A256V), 877C>T 
(R293W) and 1361G>A (R454Q) in African-Americans (91, 92) (Table 2, Figure 4a). The non-
synonymous SNP 1575A>T (K525I) is only present in African-Americans (91). OAT1-K525I 
(1575A>T) showed similar transport activity to wild type for the uptake of p-aminohippurate (PAH), 
adefovir, cidofovir and tenofovir in Xenopus laevis oocytes (91). 
  
OAT1 containing the 1361G>A (R454Q) polymorphism showed complete loss of function for the 
uptake of methotrexate (MTX), PAH and ochratoxin A (OTA) (92). No significant difference in the 
renal clearance of adefovir was observed in African-Americans heterozygous for 1361G>A (R454Q) 
(92), in contrast to the 149G>A (R50H) SNP, also expressed in African-Americans, which is associated 
with increased transport of adefovir in addition to the increased transport of cidofovir and tenofovir 
(91). Indeed kinetic analysis revealed up to a 60% reduction in the Km for some nucleoside analogs 
transported by OAT1-R50H (149G>A), when compared to the wild type OAT1 protein (91).  
 
OAT3 
More than twelve non-synonymous SNPs have been identified in the coding region of the SLC22A8 
gene, encoding OAT3 (27, 57, 69, 93). In Japanese subjects, 1166C>T (A389V) exhibited little 
difference in pravastatin clearance when compared to the wild type protein (57). The 913A>T (I305F) 
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SNP, present in Asian and African-American subjects, exhibited reduced uptake of estrone-3-sulfate and 
increased uptake of cimetidine when compared to the wild type protein (93). While confocal imaging of 
OAT3-I305F (913A>T) revealed no alterations in protein localization within the cell (93), altered 
protein folding could explain the substrate specific effects observed. Other SNPs that showed altered 
transport of estrone-3-sulfate and cimetidine include 445C>A (R149S), present in European-Americans 
and Asian-Americans, and 779T>G (I260R) and 715C>T (Q239STOP) present in Asian-Americans 
(93).  
 
 
OCT2 
OCT2 (gene symbol SLC22A2) and the splice variant OCT2-A are prevalent at the basolateral 
membrane of the proximal tubule of the kidney (94, 95). OCT2 and OCT2-A, which share 81% identity, 
differ in substrate affinity for cationic drugs such as TEA and levofloxacin (94, 95).  Several studies 
screening for genetic variants of the SLC22A2 gene have identified a number of race-specific SNPs (41, 
43, 96-98). These include 596C>T (T199I) and 602C>T (T201M) in Korean and Japanese subjects, 
493A>G (M165V), 495G>A (M165I) and 1198C>T (R400C) in African-American subjects and 
1294A>C (K432Q), which is present in both African-American and Mexican-American populations 
(98) (Figure 5).  
 
Uptake of MPP was reduced in the OCT2 protein variants containing the SNPs 495G>A (M165I), 
596C>T (T199I) and 1198C>T (R400C) in vivo (43, 98). The protein variant OCT2-A270S (808G>T), 
common to Caucasian, African, and Asian populations (98), also showed reduced transport of MPP and 
TEA (43, 98). Interestingly OCT2-K432Q (1294A>C) showed increased uptake of MPP when 
compared to the reference protein (98). Protein expression and membrane localization of OCT2 
containing 596C>T (T199I), 602C>T (T201M) and 808G>T (A270S) remained unaltered in MDCK 
cells (43) ,suggesting that such SNPs affect substrate specificity. Indeed, SNP-dependent differences in 
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the transport of MPP could offer insight into the location and structure of the substrate binding domain 
for OCT2, thus facilitating better drug design. 
 
OCT2 also transports metformin with a higher affinity than OCT1, when overexpressed in HEK293 
cells (99).  While it appears that Japanese subjects expressing the 596C>T (T199I) and 602C>T 
(T201M) polymorphisms do not influence the uptake of metformin (46), very little is known about the 
effects of the OCT SNPs identified in other ethnic groups. 
 
It remains to be determined as to whether SNPs present in OCT2 are also prevalent in OCT2A. It would 
also be of further interest to identify if such SNPs have similar effects on the uptake of drugs 
particularly as certain drugs are known to bind to OCT2A with a greater affinity when compared with 
OCT2.  
 
 
Expert Opinion 
 
Drug transporters are increasingly recognized as a therapeutic means of optimizing drug therapy. What 
must be considered more critically, nevertheless, is the clinical relevance of SNPs on drug transport. 
How much influence does the genetic variation of a particular drug transporter have on the therapeutic 
effect of a drug? To answer this question, more clinical studies are required. PEPT-1, for example, 
contains race-specific SNPs that lead to a reduction in the transport of Gly-Sar (15, 16). In vivo studies, 
to show the clinical significance of such polymorphisms, would reveal the therapeutic potential of 
PEPT1, particularly for drugs known to have low intestinal absorption rates.   
 
Conflicting data surrounding the effects of polymorphisms on the function of certain drug transporters 
augments the difficulty in determining the therapeutic significance of SNPs. Studies into the effect of 
the 521T>C (V174A) SNP in OATP1B1, for instance, yielded discrepancies in the transport data of 
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estradiol-17β–D-glucuronide and estrone-3-sulfate. Performing large haplotype studies in clinical trials 
may provide a clearer insight into the effect of 521T>C (V174A) on OATP1B1 mediated substrate 
transport.  
 
Genetic variation of OATP1B3 is also shown to alter the import of certain drugs. The SNP 1564G>T 
(G522C) was found to affect the carrier-mediated uptake of cholyltaurine, however, the effect was 
substrate specific since transport of other substrates by OATP1B3-1564G>T (G522C) showed little 
difference to wild type.  
 
Within the kidney, the race-specific SNPs 1361G>A (R454Q) and 149G>A (R50H) in OAT1, exhibited 
complete loss of function for the uptake of toxins, anticancer drugs (92) and antiviral drugs (91). An 
African-American family expressing the OAT1 variant containing 1361G>A (R454Q) showed elevated 
renal clearance of adefovir (92), highlighting the relevance of race-specific SNPs in drug therapy. The 
variant 913A>T-OAT1 (I305F), present in Asian- American and African-American subjects, exhibited 
reduced uptake of estrone sulfate and an increased uptake of cimetidine when compared to the wild type 
protein (93), further highlighting the substrate specific effects of race-specific SNPs.  
 
In most instances the effects of SNPs on transporter function is substrate specific. One possible 
explanation for this may be due to the SNP altering the drug transporter substrate-binding domain thus 
altering substrate affinity. A better understanding of the in vivo effects of SNPs on drug transport is 
required before we realize the full potential of the pharmacogenetics of drug transporters, a process 
hampered by the ever-increasing number of polymorphisms reported in bioinformatic databases. SNPs 
that result in deleterious changes in drug transporter function are typically rare in allelic frequency 
(Table 4) and thus algorithms may be used to identify SNPs that have the most pronounced effect on 
protein function. The BLOSUM62 and Grantham software, for instance, predict a decrease in OCT1 
function with SNPs that lead to structural changes in the protein (37, 40). Such software should be used 
as a predictive tool with which to focus future pharmacogenetic studies; however, caution must be taken 
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with the use of such prediction tools since threshold parameters may exclude the identification of SNPs 
with enhanced substrate uptake.    
 
Very few drugs are transported by just one carrier-mediated process and with deleterious SNPs it would 
be reasonable to assume that one transporter may compensate for the effects of the other. Drug 
metabolizing enzymes, such as cytochrome P450, are also polymorphically expressed and genetically 
determined. In addition, several examples have shown the relevance of genetic transcription factor 
variants on the expression of drug transporters. However, no study to date has investigated the impact of 
SNPs mapped to transcription factor binding domains in the promoter region of transporter genes or 
indeed intronic regions. Studies evaluating drug transporters, metabolizing enzymes and nuclear 
receptors as an integrative system, rather than individual components would offer more insight to the 
genetics of drug response. Future clinical studies looking at the genotype-phenotype relationship (Table 
3) of drug carrier variants would furthermore offer a more relevant perspective as to the role of SNPs on 
drug transport.  
 
 
Future Perspective 
 
Knowledge of the genetic variation in drug response has introduced the concept of individually tailored 
drug therapy based on genetic patient-gene profiling. DNA chips are an evolving technology that should 
make it possible for doctors to examine their patients for the presence of specific SNPs quickly and 
affordably. A single microarray can now be used to screen between 80,000 and 100,000 SNPs in a 
matter of hours and as DNA chip technology advances, SNP screening as a routine tool may become 
commonplace. Drug prescription, however, should not be exclusively based on genotype as the presence 
or absence of a particular SNP may not necessarily place them at risk of drug toxicity, for example. 
Other factors, such as lifestyle, co-medication and co-mortality must also be considered in line with a 
patient’s genetic make up. 
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Executive summary 
 
The passage of drugs through the body  
• The transport and pharmacokinetics of most drugs are dependent on uptake and efflux transporters 
expressed in the intestine, liver and kidney.  
• In addition to phase I and phase II metabolism, the uptake of a drug across the basolateral membrane 
(of hepatocytes) has been termed phase 0 metabolism, whereas final excretion represents phase III. 
 
Drug transport in the intestine  
- The peptide transporter PEPT-1  
• PEPT-1, localized to the duodenum, jejunum and ileum, is responsible for the active uptake of 
dietary peptides and hydrophilic drugs such as β–lactam antibiotics and angiotensin-converting 
enzyme (ACE) inhibitors.  
• Over 40 coding SNPs and over 100 haplotypes have been identified, of which 83T>A (F28Y), 
351C>A (S117R) and 1848G>A (L616L) are race-specific. 
• The rare protein variant PEPT-1-P586L, showed reduced transport of Gly-Sar. The PEPT-1-F28Y 
variant exhibited higher affinity to dipeptides when compared to the wild type protein. 
• Analysis into other genetic variants of PEPT-1 may reveal its potential as a target carrier for tailored 
drug therapy.  
 
Drug transport in the liver 
- OCT1 
• OCT1 is an electrogenic uniporter that transports a variety of organic cations. 
• Several race-specific OCT1 protein variants include S14F (41C>T), S189L (C566T), G401S 
(1203G>A) or M420del (1260delATG). 
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• An increase in hepatic metformin influx but a decrease in OCT1 protein suppression was observed 
in African-Americans expressing the OCT1-R488M (1222A>G) protein variant.   
- OATP1B1 
• OATP1B1 is liver-specific and transports a wide range of drug compounds. 
• 44 coding SNPs have been identified in the SLCO1B1 gene, several of which are race-specific. 
• Studies involving the OATP1B1-521T>C (V174A) variant have yielded conflicting data with 
respect to the transport of estrone-3-sulfate and estradiol-17β-D-glucuronide. 
• Significant associations between the 521T>C (V174A) SNP, present in the haplotypes OATP1B1*5 
and OATP1B1*15, and altered statin uptake were observed in vitro and in vivo.  
• The altered uptake of rifampin was further associated with the OATP1B1-521T>C (V174A) genetic 
variant. 
- OATP1B3 
• OATP1B3 is a liver-specific transporter that shares substrate recognition with OATP1B1. 
• The rare non-synonymous SNP, 1564G>T (G522C) affects the localization of OATP1B3 in 
MDCKII cells, with impaired glycosylation of the protein variant. The effect of 1564G>T (G522C) 
on OATP1B3 transport is substrate specific, since transport of cholyltaurine and 
bromosulphophthalein by OATP13-1564G>T (G522C) are reduced while transport of paclitaxel and 
estrone-3-sulfate remain unaffected. 
- OATP2B1 
• OATP2B1, expressed in the liver and intestinal epithelial cells, transports bromosulphophthalein,    
       sulfated sex steroids and fexofenadine. Transport of cholyltaurine and pravastatin only occurs at    
       acidic pH. 
• The allele OATP-B*3, present in Japanese subjects, is associated with significant reductions in the    
    Vmax of estrone-3-sulfate. 
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Drug transport in the kidney 
- OAT1 
• OAT1 containing the 1361G>A (R454Q) polymorphism exhibited abolished transport of MTX, 
PAH and OTA.  
- OAT3 
• The OAT3-I305F (913A>T) protein variant is present in Asian and African-American subjects. This 
protein variant exhibited reduced uptake of estrone-3-sulfate and increased uptake of cimetidine, 
highlighting the SNPs specific effects on substrate transport. 
- OCT2 
• Most OCT2 genetic variants show reduced transport of MPP and TEA.  
• Transport of metformin was not significantly altered in any of the OCT2 genetic variants tested.  
 
 
Expert Opinion 
• SNPs in drug transporters that are deleterious in their effects on transporter function are expressed 
with low allelic frequency and are usually race-specific. 
• Many more in vivo studies extrapolating haplotype expression of drug transporters to substrate 
uptake are required for further progress in tailored drug therapy.  
• Future studies on SNPs present in nuclear receptors that regulate the expression of drug transporters 
are necessary to elucidate their impact on drug delivery. Furthermore, the effects of SNPs in the 
promoter region and intronic regions of genes coding for drug transporters on transporter function, 
should be investigated.  
• Larger studies evaluating SNPs in drug transporters, drug metabolizing enzymes and nuclear 
receptors as part of an integrative system, although challenging, are necessary to fully comprehend 
the impact of systemic pharmacogenetics on drug therapy. 
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Future perspective 
• The implementation of electronic chips that profile a patient’s genetic make-up according to their 
drug response or susceptibility to drug toxicity may seem far-fetched, however, progress in array 
technology now allows for the use of DNA chips that screen 100, 000 SNPs in a matter of hours. 
Such technology will be of benefit in the transition of pharmacogenetics to clinical use.  
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Figure Legends: 
 
Figure 1. Drug membrane transporters in the human intestine, liver and kidney.  Members of the 
SLC21/SLCO family include OATP1B1, OATP1B3 and OATP2B1, members of the SLC22 family 
include OAT1, 2, 3 and OCT 1, 2, 3, member of the SLC47 family include MATE1 and MATE2-k, 
while members of the SLC15 family include PEPT-1 and PEPT-2. Import transporters are shown in 
white. Efflux transporters, as shown in grey, include MDR1 and MDR3, MRP1, MRP2, MRP3, MRP4 
and ABCG2. BM, basolateral membrane; AM, apical membrane; CM canalicular membrane. Import 
transporters that are tissue specific in expression and/or the most highly abundant are discussed in this 
review. These include PEPT-1 in the intestine OCT1, OATP1B1, OATP1B3 and OATP2B1 in the liver 
and OAT1, OAT3 and OCT2 in the kidney. 
 
Figure 2. Predicted secondary structure of PEPT-1. The coding, non-synonymous SNPs most highly 
studied are shown. 
 
Figure 3. Predicted secondary structure of (a) OATP1B1 and (b) OATP1B3. The coding, non-
synonymous SNPs most highly studied are shown in boxes. In OATP1B1 the controversial SNP V174A 
(521T>A) is highlighted. 
 
Figure 4. Predicted secondary structure of (a) OAT1 and (b) OAT3. The coding, non-synonymous 
SNPs most highly studied are shown. In OAT3 most SNPs are clustered in loop 6. 
 
Figure 5. Predicted secondary structure of OCT2. The coding, non-synonymous SNPs most highly 
studied are shown . 
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Table 1. Import transporters, classified according to their protein groups, are expressed in various tissues of the human body. Tissues highlighted in bold-
type indicate the highest level of protein expression. 
 
 
IMPORT 
CARRIERS 
Tissue Distribution References IMPORT 
CARRIERS 
Tissue Distribution References 
OAT family  [(100-103) OATP family  (28, 29, 31, 104) 
OAT1 Kidney, brain, eye  OATP1A2   Brain, liver, kidney, eye  
OAT2 Liver, Kidney  OATP2B1   Brain, liver, kidney, Intestine, 
placenta 
 
OAT3 Blood cerebrospinal fluid barrier, 
liver, Kidney, eye  
 OATP1B1   Liver  
OAT4 Liver, placenta, kidney  OATP3A1  Ubiquitous  
OAT5 Liver, kidney  OATP4A1  Ubiquitous  
   OATP1C1  Brain, testis, heart lung, eye  
OCT family  (33, 105) OATP1B3  Liver  
OCT1 Liver, Intestine, lung, heart, 
placenta 
    
OCT2 Liver, Kidney, brain, Intestine     
OCT3 Liver, Intestine, Pancreas, Brain, 
heart 
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IMPORT 
CARRIERS 
Tissue Distribution References IMPORT 
CARRIERS 
Tissue Distribution References 
OCTN family  [(23, 106)  PEPT family  (15, 107)  
OCTN1 Kidney, liver, testis  PEPT1 Liver, Kidney, Intestine  
OCTN2 Kidney, liver, brain, intestine, testis  PEPT2 Kidney, Intestine  
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Table 2. A summary of the effects of SNPs on the transport activity of PEPT-1, OCT1, OATP1B1, OATP1B3, OATP2B1, OAT1, OAT3 and OCT2. 
SNPs highlighted in bold-type represent non-synonymous changes. AJ: Ashkenazi Jewish, SSA: Sub-Saharan African, NSA: North Saharan African, AA: 
African-American, ASM: Asian American, JA: Japanese, KO: Korean, SEA: South East Asian, CH: Chinese, IP: Indo-Pakistani, HI: Hispanic, PI: Pacific 
Islander, SP: South Pacific, ME: Mexican American, CA: Caucasian, NE: North European, SWA: South West American, SA: South American.    reduced 
transport,   increased transport,        no difference,  a: abolished transport, n: no transport. 
 Drug 
Transporter 
Nucleotide 
Position 
Amino Acid 
Position Ethnic Bias In vitro Transport  In vivo Transport  Reference 
Intestine PEPT1 61G>A V21I AA cephalexin  (15, 16) 
  83T>A F28Y AA cephalexin  (15, 16) 
  258G>A G86G AA   (15, 16) 
  330C>T N110N AA   (15, 16) 
  342C>T T114I  glycyl-sarcosine  (15, 16) 
  350G>A 
 
S117N 
 
AA, CA, ASM, HI, 
PI 
glycyl-sarcosine 
cephalexin 
 (15, 16) 
 
  351C>A S117R AA cephalexin  (17) 
  
364G>A V122M 
AA glycyl-sarcosine 
cephalexin 
 
(15, 16) 
  843G>A V281V ASM   (15, 16) 
  1179C>T N393N AA, ASM   (15, 16) 
  1248G>C V416L  glycyl-sarcosine  (15, 16) 
  
1256G>C G419A 
AA, CA, AS, HI glycyl-sarcosine 
cephalexin 
 (17) 
 
  1348C>T A449A AA, CA, AS, HI, PI   (15, 16) 
  1348G>A V450I AA, ASM, HI, PI glycyl-sarcosine  (15, 16) 
  
1352C>A T451N 
AA, CA, ASM glycyl-sarcosine 
cephalexin 
 (15, 16) 
 
  1377C>T R459C  glycyl-sarcosine  (15, 16) 
  1446A>G E482E AA   (15, 16) 
  1527C>T N509N AA, CA, HI   (15, 16) 
  1609C>T P537S AA cephalexin   (15, 16) 
  1758C>T P586L  glycyl-sarcosine  (15, 16) 
  1848G>A 
 
L616L 
 
CA   (15, 16) 
 
 35 
 Drug 
Transporter 
Nucleotide 
Position 
Amino Acid 
Position Ethnic Bias In vitro Transport  In vivo Transport  Reference 
Liver OCT1 41C>T S14F 
AA 1-methyl 1-4-phenylpyridinum 
metformin  
metformin 
(40, 45) 
  123C>G F41L    (38) 
  156T>C S52S KO   (38) 
  181C>T R61C 
EA, ME 1-methyl 1-4-phenylpyridinum 
metformin 
 
(37, 40, 42) 
  243C>T G81G    (38) 
 
 
262T>C 
 
 
C88R 
 
 
 1-methyl 1-4-phenylpyridinum 
Serotonin 
tetraethylammonium bromide 
 (37, 40, 42) 
 
 
  350C>T P117L    (38) 
  480C>G F160L 
KO, AA, EA, AS, 
ME 
  
(38) 
  566C>T S189L  metformin  (45) 
  659G>T G220V AA 1-methyl 1-4-phenylpyridinum   (37, 40, 42) 
  848C>T P283L KO 1-methyl 1-4-phenylpyridinum   a  (37, 43) 
  859C>G R287G  1-methyl 1-4-phenylpyridinum   a  (37, 43) 
  1022C>T P341L KO, AA, AS 1-methyl 1-4-phenylpyridinum metformin (37, 40, 42) 
 
 
1203G>A 
 
 
G401S 
 
 
AA, EA 1-methyl 1-4-phenylpyridinum 
Serotonin 
tetraethylammonium bromide 
metformin 
 
(37, 40, 42, 
45) 
 
  1222A>G M408V AA  metformin  (38) 
  1260delATG M420del AA, EA, ME metformin metformin (45) 
  1393G>A G465R 
 1-methyl 1-4-phenylpyridinum 
metformin 
  
(37, 40, 42) 
 
 
217T>C 
 
 
F73L 
 
 
EA rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52) 
 
 
  245T>C V82A EA   (52) 
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Drug 
Transporter 
Nucleotide 
Position 
Amino Acid 
Position Ethnic Bias In vitro Transport  In vivo Transport  Reference 
Liver 
continued… 
OATP1B1 
 
 
 
 
388A>G 
 
 
 
 
 
 
N130D 
 
 
 
 
 
 
AA, EA, JP estrone-3-sulfate 
estradiol-17β–D-glucuronide 
Rosuvastatin 
pravastatin 
atorvastatin 
cholesterol 
simastatin 
pravastatin 
rosuvastatin 
pitavastatin      
(50, 52, 54, 
56, 57, 59, 
63, 64)  
  411G>A S137S    (52) 
  452A>G N151S JP  pravastatin (57) 
 
 
455G>A 
 
 
R152K 
 
 
 rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52) 
 
 
 
 
463C>A 
 
 
P155T 
 
 
AA, EA, JP rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (50, 52) 
 
 
 
 
467A>G 
 
 
E156G 
 
 
EA rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52, 108) 
 
 
 
 
521T>C 
 
 
 
 
 
V174A 
 
 
 
 
 
AA, EA, JP estrone-3-sulfate 
estradiol-17β–D-glucuronide 
Rosuvastatin 
repaglinide 
pravastatin  
pravastatin 
rosuvastatin 
pitavastatin 
fexofenadine 
repaglinide 
cholesterol 
(50-52, 54, 
57, 58, 61, 
68, 108, 109) 
 
 
 
  571C>T L191L    (52) 
  578T>G L193R  estradiol-17β–D-glucuronide  (52, 68, 108) 
  597C>T F199F    (52) 
 
 
721G>A 
 
 
D241N 
 
 
 rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52) 
 
 
  1007C>G P336R JP   (52, 68, 108) 
 
 
1058T>C 
 
 
I353T 
 
 
EA rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52, 68, 108) 
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 Drug 
Transporter 
Nucleotide 
Position 
Amino Acid 
Position Ethnic Bias In vitro Transport  In vivo Transport  Reference 
Liver 
continued… 
OATP1B1 
 
 
1294A>G 
 
 
N432D 
 
 
EA rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52) 
 
 
 
 
 
1385A>G 
 
 
D462G 
 
 
EA rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52, 108) 
 
 
  1454G>T C485F JP rosuvastatin   (57) 
  1463G>C G488A AA rosuvastatin   (52, 108) 
 
 1628T>G L543W 
  pravastatin 
(myopathy) 
(60) 
 
  1929A>C L643F CA  pravastatin (50) 
 
 1964A>G D655G 
EA rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52, 108) 
 
 
 
 
 
2000A>G 
 
 
E667G 
 
 
AA, EA rifampin 
estrone-3-sulfate 
estradiol-17β–D-glucuronide 
 (52, 108) 
 
 
        
 OATP1B3 
 
334T>G 
 
S112A 
 
CA bromosulphophthalein 
bile acid 
 (74, 75) 
 
 
 
699G>A 
 
M233I 
 
CA bromosulphophthalein 
bile acid  
(74, 75) 
 
  1272A>G L424L    (69) 
  1557A>G A519A     (69) 
 
 
1564G>T 
 
G522C 
 
CA bromosulphophthalein 
bile acid 
 (75) 
 
   1833G>A G611G    (69) 
        
 OATP2B1 1175C>T T392I  estrone-3-sulfate  (51) 
  1457C>T S486F  estrone-3-sulfate  (51) 
        
 
OCT1 41C>T S14F 
AA 1-methyl 1-4-phenylpyridinum 
metformin  
metformin 
(40, 45) 
  123C>G F41L    (38) 
  156T>C S52S KO   (38) 
 
 181C>T R61C 
EA, ME 1-methyl 1-4-phenylpyridinum 
metformin 
 
(37, 40, 42) 
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 Drug 
Transporter 
Nucleotide 
Position 
Amino Acid 
Position Ethnic Bias In vitro Transport  In vivo Transport  Reference 
Liver  OCT1 243C>T G81G    (38) 
continued… 
 
262T>C 
 
 
C88R 
 
 
 1-methyl 1-4-phenylpyridinum 
Serotonin 
tetraethylammonium bromide 
 (37, 40, 42) 
 
 
 
 350C>T P117L 
   
(38) 
 
 480C>G F160L 
KO, AA, EA, AS, 
ME 
  
(38) 
  566C>T S189L  metformin  (45) 
  659G>T G220V AA 1-methyl 1-4-phenylpyridinum   (37, 40, 42) 
  848C>T P283L KO 1-methyl 1-4-phenylpyridinum   a  (37, 43) 
  859C>G R287G  1-methyl 1-4-phenylpyridinum   a  (37, 43) 
  1022C>T P341L KO, AA, AS 1-methyl 1-4-phenylpyridinum metformin (37, 40, 42) 
 
 
1203G>A 
 
 
G401S 
 
 
AA, EA 1-methyl 1-4-phenylpyridinum 
Serotonin 
tetraethylammonium bromide 
metformin 
 
(37, 40, 42, 
45) 
 
  1222A>G M408V AA  metformin  (38) 
  1260delATG M420del AA, EA, ME metformin metformin (45) 
 
 1393G>A G465R 
 1-methyl 1-4-phenylpyridinum 
metformin 
  
(37, 40, 42) 
        
Kidney 
   
    
 
 
OAT1 20T>C L7P SEA 
  (27)  
 
 
 
149G>A 
 
 
 
R50H 
 
 
 
SSA, AA, MA 
 
 
 
Antivirals  
ocratoxin A 
 p-aminohippurate 
methotrexate 
 (92) 
 
 
 
  180C>T N60N ASM   (91) 
 
 
252G>T 
 
 
P84P 
 
 
JA, AJ, NSA, CA, 
AA, AS, ME, NE 
 
ocratoxin A 
 p-aminohippurate 
methotrexate 
 (91) 
 
 
  311C>T P104L CA   (92) 
 
 
351A>G 
 
 
P117P 
 
 
CA, AA, AS, JA, 
AJ, NSA, CA, ME, 
NE 
  (91) 
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 Drug 
Transporter 
Nucleotide 
Position 
Amino Acid 
Position Ethnic Bias In vitro Transport  In vivo Transport  Reference 
Kidney  OAT1 582C>G L194L    (91) 
Continued… 
 
677T>C 
 
 
I226T 
 
 
CA 
 
 
ocratoxin A 
p-aminohippurate 
methotrexate 
 (92) 
 
 
 
 
767C>T 
 
 
A256V 
 
 
AA 
 
 
ocratoxin A 
p-aminohippurate 
methotrexate 
 (92) 
 
 
  837G>A G279G    (91) 
 
 
877C>T 
 
 
R293W 
 
 
AA 
 
 
ocratoxin A 
p-aminohippurate 
methotrexate 
 (92) 
 
 
  1233C>T L411L ASM, IP   (91) 
 
 
 
1361G>A 
 
 
R454Q 
 
 
AA 
 
 
ocratoxin A                               n 
p-aminohippurate                     n 
methotrexate                            n 
 (92) 
 
 
  1470C>T Y490Y AA   (91) 
 
 
1575A>T 
 
K525I 
 
AA 
 
Antivirals 
p-aminohippurate 
Adefovir (92) 
 
        
 
OAT3 
153G>A 
 
P51P 
 
IP, JA, SEA, SSA, 
AJ, NSA, NE 
  (69) 
 
 
 
387C>A 
 
F129L 
  
estrone-3-sulfate 
cimetidine 
 (93) 
 
 
 
445C>A 
 
R149S 
 
EA 
 
estrone-3-sulfate                     n 
cimetidine                                n 
 (93) 
 
  523A>G I175V JA   (93) 
  715C>T Q239STOP  ASM     (69) 
 
 723T>A T241T 
CH, IP, SP, SA, 
SSA, AJ, NSA, PA, 
SWA, NE 
estrone-3-sulfate                     n 
cimetidine                                n 
 (93) 
 
 
 
 
779T>G 
 
I260R 
 
ASM 
 
estrone-3-sulfate                     n 
cimetidine                               n 
 (93) 
 
 
829C>T 
 
R277W 
  
estrone-3-sulfate 
cimetidine 
 (93) 
 
 
842T>C 
 
V281A 
  
estrone-3-sulfate 
cimetidine 
 (93) 
 
 
913A>T 
 
I305F 
 ASM, AA, 
estrone-3-sulfate 
cimetidine 
 (93) 
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 Drug 
Transporter 
Nucleotide 
Position 
Amino Acid 
Position Ethnic Bias In vitro Transport  In vivo Transport  Reference 
Kidney  OAT3 929C>T A310V    (93) 
Continued… 
 
1166C>T 
 
A389V 
 
 estrone-3-sulfate 
cimetidine 
 (57) 
 
 
1195G>T 
 
A399S 
 
 estrone-3-sulfate 
cimetidine 
 (93) 
 
 
1342G>A 
 
V448I 
 
 estrone-3-sulfate 
cimetidine 
 (93) 
        
 OCT2 160C>T P54S AA   (98) 
 
 390G>T T130T 
CA, AA, AS, ME, 
PI 
  (43, 97, 98) 
  481T>C F161L CA    (97, 98) 
  493A>G M165V AA 1-methyl 1-4-phenylpyridinum  (98) 
  495G>A M165I AA   (98) 
 
 596C>T T199I 
AS 1-methyl 1-4-phenylpyridinum 
tetraethylammonium bromide 
metformin  (43, 96, 99) 
 
 602C>T T201M 
AS 1-methyl 1-4-phenylpyridinum 
tetraethylammonium bromide 
metformin  (43, 96, 99) 
 
 808G>T A270S 
CA, AA, ASM, ME, 
PI 
1-methyl 1-4-phenylpyridinum 
tetraethylammonium bromide 
 (43, 98) 
  890C>G A297G CA   (80, (98) 
  1198C>T R400C AA 1-methyl 1-4-phenylpyridinum  (98) 
  1203C>T I401I CA 1-methyl 1-4-phenylpyridinum  (98) 
  1294A>C K432Q AA, ME   (98) 
  1398C>T G466G AA   (98) 
 
 1506G>A V502V 
CA, AA, ASM, ME, 
PI 
  (43, 97, 98) 
  1587C>T A529A AS   (98) 
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Table 3. Genotype-phenotype association of PEPT1, OATP1B1, OATP1B3, OCT1, OAT1 and OAT3. 
 
 
Drug 
Transporter 
Genotype Drug Substrate Phenotype References 
PEPT1   No studies conducted  
OCT1 41C>T 
566C>T 
1200G>A 
1791delATG 
Metformin Increased plasma glucose concentrations and prolonged plasma insulin 
levels 
(76) 
OATP1B1 521T>C 
388A>G + 521T>C 
-11187G>T 
Pravastatin 
Repaglinide 
Repaglinide 
Increased myopathy 
Reduced levels of total cholesterol and LDL cholesterol 
Increased plasma glucose concentrations 
(32, 39, 41, 43) 
(48) 
(48) 
 
OATP1B3   No studies conducted  
OATP2B1   No studies conducted  
OAT1   No studies conducted  
OAT3   No studies conducted  
OCT2 T199I  
T201M 
Metformin No significant phenotypic changes  (98) 
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Table 4. Summary of the allelic frequencies for coding, non-synonymous SNPs present in PEPT-1, OCT1, OATP1B1, OATP1B3, OATP2B1, OAT1, 
OAT3 and OCT2.  Allele frequencies for each SNP were obtained from www.ncbi.nih.nlm.gov/snp. More than one frequency number for the same SNP is 
given in some instances, according to multiple data submitted to the database. SNPs not assinged a ‘rs’ reference number have not been submitted to 
NCBI. The following abbreviations are given in accordance with the NCBI database- AF: unknown population, AFR/ASP: African-American, YRI: Sub-
Saharan Africans, JPT: Japanese, CHN: Asian, HCB: Han-Chinese, CEU: Caucasian-American and EUR: European. N.D. refers to non-determined allelic 
frequencies. 
 
Allele frequency  Nucleotide 
change 
Amino acid 
change 
Reference 
AF AFR/ASP YRI JPT CHN HCB CEU EUR 
PEPT-1 61G>A V21I rs45513193 0.004        
 83T>A F28Y rs45562741 0.004        
 342C>T T114I          
 350G>A S117N rs2297322 0.250 0.402 0.231 0.442 0.467  0.367 0.092  
 351C>A S117R rs8187821 0.002        
 364G>A V122M rs8187820 0.008 0.013 0.067 0  0 0  
 1248G>C V416L          
 1256G>C G419A rs4646227 0.139 0.109   0.079 0.058 
0.023 
0.022 0.104 
0.133  
 0.102 0.017 0.042 
 1348G>A V450I rs2274828 0.070        
 1352C>A T451N rs8187838 0.060 0 0 0 0 0 0.033   0.017 0.021 
 1377C>T R459C rs2274827 0.033 0 0 0.056  0.045 0.083 0.044 
0.008 
0 0 
 1609C>T P537S rs8187830 0.002 0.013 0 0.012  0 0  
 1758C>T P586L          
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 Nucleotide change 
Amino acid 
change Reference Allele frequency 
    AF AFR YRI JPT CHN HCB CEU EUR 
OCT1 41C>T S14F rs45504100 0.013        
 123C>G F41L rs2297373 N.D.        
 181C>T R61C rs12208357 0.031        
 262T>C C88R          
 350C>T P117L          
 480C>G F160L rs683369   0 0.111  0.114  0.100 
0.203  
0.208  
 566C>T S189L rs45607934 0.002        
 659G>T G220V rs45447195 0.002        
 848C>T P283L rs4646277 N.D.        
 859C>G R287G rs4646278 N.D.        
 1022C>T P341L rs2282143 0.047  0.108 0.193  0.244 0  
 1203G>A G401S rs45512393 0.008        
 1222A>G M408V rs628031 0.682   0.660 0.841 
0.767  
0.783 
0.822  
0.811 0.729 
0.856   
0.852 
0.583  
0.612 0.562 
 1260delATG M420del rs45542538 0.105        
   rs45465102 0.105        
   rs45545341 0.105        
 1393G>A G465R rs34059508 N.D.        
   rs45476695 0.048        
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 Nucleotide change 
Amino acid 
change Reference Allele frequency 
    AF AFR YRI JPT CHN HCB CEU EUR 
OATP1B1 217T>C F73L          
 245T>C V82A          
 388A>G N130D rs2306283 0.364 0.717 0.814 0.644  0.636 0.729 0.844 0.392 0.396 
 452A>G N151S rs2306282  0 0 0.017 
0.011 
0.044   0.021 
0 
0.034 
0 
0.033 0 
 455G>A R152K          
 463C>A P155T rs11045819 0.148 0.022 0.058 0 0 0.011 0.144  0.150 0.229 
 467A>G E156G          
 521T>C V174A rs4149056 0.122 0.022 0.008 0.100 0.125 0.156 0.158  0.161 0.083 
 578T>G L193R          
 721G>A D241N          
 1007C>G P336R          
 1058T>C I353T          
 1294A>G N432D          
 1385A>G D462G          
 1454G>T C485F          
 1463G>C G488A          
 1628T>G L543W          
 1929A>C L643F rs34671512   0.067 0  0 0.058  
 1964A>G D655G          
 2000A>G E667G          
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 Nucleotide change 
Amino acid 
change Reference Allele frequency 
    AF AFR YRI JPT CHN HCB CEU EUR 
OATP1B3 334T>G S112A rs4149117  0.348 0.342 0.350 
0.670 
0.667 0.826 0.711 0.867 0.891 
 699G>A M233I rs7311358  0.348 0.342 0.714  0.678 0.841 
0.711  
 0.744 
0.881  
0.867 0.896 
 1564G>T G522C          
            
            
OATP2B1 1175C>T T392I rs1621378   0 0  0.011 0 0 
 1457C>T S486F rs2306168  0.095  0.273 
0.417  
0.405 
0.378 
0.360 0.250 
0.289 
0.256 
0.067  
0.060 0 
            
            
OAT1 20T>C L7P          
 149G>A R50H rs45564337 0.011        
 311C>T P104L rs11568627 0.002 0.014       
 677T>C I226T rs45482591 0.002        
 767C>T A256V rs45482701 0.002        
 877C>T R293W rs45607933 0.006        
 1361G>A R454Q rs45469996 0.002        
 1575A>T K525I          
            
OAT3 387C>A F129L rs45512894 0.002        
 445C>A R149S rs45566039 0.004        
 523A>G I175V          
 715C>T Q239STOP rs45516999 0.002        
 779T>G I260R rs45513295 0.002        
 829C>T R277W rs45545636 0.002        
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 Nucleotide change 
Amino acid 
change Reference 
Allele 
frequency        
    AF AFR YRI JPT CHN HCB CEU EUR 
 842T>C V281A rs45438191 0.017  0.058 0.033  0.022 0  
 913A>T I305F rs45577232 0.009        
 929C>T A310V rs45511192 0.002        
 1166C>T A389V          
 1195G>T A399S rs45604034 0.002        
 1342G>A V448I rs45627136 0.007        
     
            
OCT2 481T>C F161L rs45591037 0.002        
 493A>G M165V rs45520136 0.002        
 495G>A M165I rs45482799 0.006  0 0  0  0 
 596C>T T199I          
 602C>T T201M          
 808G>T A270S rs316019 0.127 0.220 0.130 
0.183  
0.158 
0.122  
0.057 0.208 
0.133 
0.122 0.075 0.062 
 890C>G A297G rs45592541 0.010        
 1198C>T R400C rs8177516 0.006 0.022 0.009 0 0 0 0 0 
 1294A>C K432Q rs8177517 0.058 0.022 0.058 0 0 0 0 0 
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